Phosphorylcholine

Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases

Retrieved on: 
Thursday, May 19, 2022
Central retinal vein occlusion, Ibex, U.S. Securities and Exchange Commission, Phosphorylcholine, Drug Quality and Security Act, Diabetic retinopathy, Private Securities Litigation Reform Act, CHF, GLOW, DME, Risk, Nasdaq, CN, Biologics license application, News, GLIMMER, Nature, VEGF, BLA, Research, Securities Act of 1933, Intention, Pathology, Severe cognitive impairment, CORE, Retina, Science, Uncertainty, FDA, PALO, Therapy, Securities Exchange Act of 1934, MD, Security (finance), SIX Swiss Exchange, GLEAM, RVO, KOD, Patient, Form 10-Q, AMD, CH, Forward-looking statement, Safety, Glaucoma, ABC, IL-6, Conseil national du numérique, Fine chemical, Pharmaceutical industry, Ursus

Kodiak Sciences leverages its core technology, the Antibody Biopolymer Conjugate (ABC) PlatformTM, to develop next-generation, long-durability ophthalmic therapies.

Key Points: 
  • Kodiak Sciences leverages its core technology, the Antibody Biopolymer Conjugate (ABC) PlatformTM, to develop next-generation, long-durability ophthalmic therapies.
  • Lonza will support Kodiak in scaling up and securing supply chain as Kodiak progresses towards BLA readiness and potential commercial launch to meet growing market demand.
  • KSI-501 is a dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases.
  • Kodiak, Kodiak Sciences, ABC, ABC Platform and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

2020 Global Drug-Eluting Stents Market Analysis, by Product, Application, End User and Region

Retrieved on: 
Wednesday, December 23, 2020
Interventional cardiology, Drug-eluting stent, Medical technology, Medicine, Stent, Medical equipment, Phosphorylcholine, Biosensors International

DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Global Drug-Eluting Stents Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Global Drug-Eluting Stents Market" report has been added to ResearchAndMarkets.com's offering.
  • The report also includes market projections through 2024 and the market rank for key market players.
  • The report details the market share of drug-eluting stents based on types of products, applications and end-user.
  • By product type, the market is segmented into polymer-based drug-eluting stents and polymer-free drug-eluting stents.

Global Drug-Eluting Stents Market

Retrieved on: 
Monday, November 9, 2020
Interventional cardiology, Medical technology, Medicine, Drug-eluting stent, Medical devices, Medical specialties, Stent, Biotronik, Market share analysis, Phosphorylcholine, Zotarolimus

The report also includes market projections through 2024 and the market rank for key market players.

Key Points: 
  • The report also includes market projections through 2024 and the market rank for key market players.
  • By product type, the market is segmented into polymer-based drug-eluting stents and polymer-free drug-eluting stents.By application, the market is segmented into coronary artery disease (CAD) and peripheral artery disease (PAD).
  • - Estimation of the market size and analyses of market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
    - Market share analysis of the drug-eluting stents based on product, application, end-use, and region
    - Assessment of market dynamics for drug-eluting stents with market drivers and restraints explained, medical device regulations, market background and pipeline analysis of the stents
    - Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
    - Company profiles of the leading market players, including Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corp., Medtronic Plc and Cook Medical Inc.
  • The global market for drug-eluting stents was valued at REDACTED in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach REDACTED by 2024.

Kansai University Research: Cell Membrane-inspired Phospholipid Polymers as New Generation of Biomaterials for Medical Devices

Retrieved on: 
Monday, June 15, 2020
Organic compounds, Chemistry, Biotechnology, Articles, Biosensors, Phosphorylcholine, Polyether ether ketone, Biofouling, Yasuhiko Iwasaki

Modern biosensors used as medical diagnostic devices are based on detecting antibody-antigen type reactions between proteins on micro-arrays patterned on solid substrates made of materials including plastics and semiconductors.

Key Points: 
  • Modern biosensors used as medical diagnostic devices are based on detecting antibody-antigen type reactions between proteins on micro-arrays patterned on solid substrates made of materials including plastics and semiconductors.
  • With the aim of developing biocompatible substrates for diagnostic devices, a team led by Yasuhiko Iwasaki at Kansai University in Japan has patterned substrates using antifouling poly[2-methacryloyloxyethyl phosphorylcholine (MPC) polymers with residues of tyrosine.
  • Optical and XPS measurements showed that this process created low friction-grafting layers of zwitterionic polymers on the PEEK samples.
  • "Thus, we conclude that the surface modication of PEEK with MPC and MBPP can provide ideal surface properties for orthopedic devices.

Kansai University Research: Cell Membrane-inspired Phospholipid Polymers as New Generation of Biomaterials for Medical Devices

Retrieved on: 
Monday, June 15, 2020
Organic compounds, Chemistry, Biotechnology, Articles, Biosensors, Phosphorylcholine, Polyether ether ketone, Biofouling, Yasuhiko Iwasaki

Modern biosensors used as medical diagnostic devices are based on detecting antibody-antigen type reactions between proteins on micro-arrays patterned on solid substrates made of materials including plastics and semiconductors.

Key Points: 
  • Modern biosensors used as medical diagnostic devices are based on detecting antibody-antigen type reactions between proteins on micro-arrays patterned on solid substrates made of materials including plastics and semiconductors.
  • With the aim of developing biocompatible substrates for diagnostic devices, a team led by Yasuhiko Iwasaki at Kansai University in Japan has patterned substrates using antifouling poly[2-methacryloyloxyethyl phosphorylcholine (MPC) polymers with residues of tyrosine.
  • Optical and XPS measurements showed that this process created low friction-grafting layers of zwitterionic polymers on the PEEK samples.
  • "Thus, we conclude that the surface modication of PEEK with MPC and MBPP can provide ideal surface properties for orthopedic devices.

Coronary Stents Market - Global Forecast to 2026: Technological Advancement in Stent Development to Minimize Restenosis and Improve Patient Compliance

Retrieved on: 
Monday, September 24, 2018
Medicine, Interventional cardiology, Clinical medicine, Medical devices, Drug-eluting stent, Percutaneous coronary intervention, Coronary stent, Restenosis, Stent, Bare-metal stent, Phosphorylcholine

The global coronary stents market was valued at US$ 6,216.7 Mn in 2017, and is expected to reach US$ 11,622.5 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.

Key Points: 
  • The global coronary stents market was valued at US$ 6,216.7 Mn in 2017, and is expected to reach US$ 11,622.5 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.
  • In the last 2 decades there has been technological advancement in the manufacturing of stents to counteract complication such as restenosis and stent-in-stent procedure.
  • The only limitation the coronary stents market face is the exorbitant price of drug eluting stents and competition exerted by percutaneous coronary intervention.
  • Drug eluting stents are currently dominating the coronary stents market on account of key factors such as rising prevalence of coronary artery stenosis, technological advancement in the formulation of biodegradable polymers containing antiproliferative agents to prevent restenosis.